News Articles

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult... CAMBRIDGE, Mass. & OSAKA, Japan -Monday 17 December 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin)...

Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners -Thursday 13 December 2018  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their commitment to and excellence in regenerative medicine. The 2019 Winner of the Senior...

Takeda Shareholders Approve Resolutions Related to the Proposed Acquisition of Shire plc -Thursday 6 December 2018

(BUSINESS WIRE)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today...

Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating... -Wednesday 5 December 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent oral NINLARO™ (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who...

Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc -Wednesday 5 December 2018

(BUSINESS WIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or...

European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients... -Thursday 29 November 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small...

Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc -Sunday 25 November 2018

(BUSINESS WIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has...

Takeda Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in Relation to the... -Wednesday 14 November 2018

(BUSINESS WIRE) -- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited (“Takeda” or the “Company”) regarding the proposed acquisition (the “Acquisition”) of Shire plc (“Shire”), Takeda announces the publication of a circular (the “Circular”)...

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for... -Monday 5 November 2018

– Results from Phase 3 Studies Including TOURMALINE-MM3 Trial of NINLARO™ (ixazomib) as Post- Autologous Stem Cell Transplant Maintenance Therapy and ECHELON-2 Trial of ADCETRIS® (brentuximab vedotin) in Frontline CD30-Positive Peripheral T-Cell Lymphoma Featured in Oral Sessions...

Takeda Reports Second Quarter FY2018 Results -Thursday 1 November 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue +4.2%, led by Growth Drivers, with growth in every region Underlying Revenue was solid at +4.2%, with continued strong momentum from Takeda's Growth Drivers (Gastroenterology, Oncology,...

Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc -Sunday 28 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today issued the following statement with regard to its discussions with the European Commission (“EC”) as part of its Phase 1 review of the proposed acquisition of Shire plc (“Shire”) announced on May 8,...

Takeda to Highlight Data in Hodgkin Lymphoma During the 11th International Symposium on Hodgkin... -Sunday 28 October 2018

– Six Abstracts to be Presented to Highlight the Potential Impact of ADCETRIS® (brentuximab vedotin) for the Treatment of Hodgkin Lymphoma – (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of six...

Takeda Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and... -Saturday 27 October 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or “Takeda”) announces that it has today entered into a Senior Short Term Loan Facility Agreement (the “SSTL”) for an aggregate principal amount of up to 500 billion Japanese Yen. The SSTL will finance...

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG®... -Tuesday 23 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective...

Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at... -Monday 22 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance...

Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc -Friday 19 October 2018

(BUSINESS WIRE)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has...

Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders -Monday 1 October 2018

(BUSINESS WIRE) -- Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or the “Company”) today announced that the Company has established the record date...

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of... -Saturday 29 September 2018

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed...

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+... -Sunday 23 September 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG®(brigatinib) as a monotherapy for...

Takeda Reports First Quarter FY2018 Results -Thursday 2 August 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +6.4% with growth in every region Underlying Revenue grew +6.4%, led by Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) displaying strong growth of...